Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 2, 2020 4:01 PM EST Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets
 U.S. Product Revenue Increased Five-fold During the Third Quarter
 ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid and ezetimibe) in Germany, the Largest European Market
Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2020, and... More
